|
Name |
Hypoxylonol B
|
Molecular Formula | C21H18O5 | |
IUPAC Name* |
(11R,17S,19S)-7,15,19-trihydroxy-17-methoxypentacyclo[10.7.1.02,11.03,8.016,20]icosa-1,3(8),4,6,12(20),13,15-heptaen-9-one
|
|
SMILES |
CO[C@H]1C[C@@H](C2=C3[C@H](CC(=O)C4=C3C=CC=C4O)C5=C2C1=C(C=C5)O)O
|
|
InChI |
InChI=1S/C21H18O5/c1-26-16-8-15(25)21-17-10-3-2-4-12(22)18(10)14(24)7-11(17)9-5-6-13(23)20(16)19(9)21/h2-6,11,15-16,22-23,25H,7-8H2,1H3/t11-,15+,16+/m1/s1
|
|
InChIKey |
VNVXZDRVVHCQPB-RLCCDNCMSA-N
|
|
Synonyms |
Hypoxylonol B; CHEMBL1950967; (1S)-1beta,4,9-Trihydroxy-3alpha-methoxy-1,2,3,6balpha,7,8-hexahydrobenzo[j]fluoranthene-8-one
|
|
CAS | NA | |
PubChem CID | 57333864 | |
ChEMBL ID | CHEMBL1950967 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 350.4 | ALogp: | 1.5 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 26 | QED Weighted: | 0.725 |
Caco-2 Permeability: | -5.057 | MDCK Permeability: | 0.00001660 |
Pgp-inhibitor: | 0.235 | Pgp-substrate: | 0.998 |
Human Intestinal Absorption (HIA): | 0.537 | 20% Bioavailability (F20%): | 0.976 |
30% Bioavailability (F30%): | 0.992 |
Blood-Brain-Barrier Penetration (BBB): | 0.056 | Plasma Protein Binding (PPB): | 94.91% |
Volume Distribution (VD): | 1.036 | Fu: | 2.66% |
CYP1A2-inhibitor: | 0.105 | CYP1A2-substrate: | 0.892 |
CYP2C19-inhibitor: | 0.079 | CYP2C19-substrate: | 0.624 |
CYP2C9-inhibitor: | 0.569 | CYP2C9-substrate: | 0.961 |
CYP2D6-inhibitor: | 0.289 | CYP2D6-substrate: | 0.295 |
CYP3A4-inhibitor: | 0.248 | CYP3A4-substrate: | 0.547 |
Clearance (CL): | 2.845 | Half-life (T1/2): | 0.062 |
hERG Blockers: | 0.261 | Human Hepatotoxicity (H-HT): | 0.794 |
Drug-inuced Liver Injury (DILI): | 0.828 | AMES Toxicity: | 0.854 |
Rat Oral Acute Toxicity: | 0.914 | Maximum Recommended Daily Dose: | 0.971 |
Skin Sensitization: | 0.666 | Carcinogencity: | 0.102 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.159 |
Respiratory Toxicity: | 0.952 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002854 | 0.863 | D0H6QU | 0.340 | ||||
ENC002856 | 0.810 | D07MGA | 0.327 | ||||
ENC004967 | 0.741 | D0H1AR | 0.298 | ||||
ENC003957 | 0.537 | D01XDL | 0.295 | ||||
ENC003958 | 0.537 | D01XWG | 0.294 | ||||
ENC003961 | 0.490 | D07VLY | 0.288 | ||||
ENC002122 | 0.490 | D0C9XJ | 0.288 | ||||
ENC003960 | 0.474 | D0R9WP | 0.276 | ||||
ENC000987 | 0.422 | D08NQZ | 0.276 | ||||
ENC005474 | 0.422 | D0S0LZ | 0.276 |